Arthrex, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Naples FL United States (1981)
Status: No NME R&D (1981)

Organization Overview

First Clinical Trial
2010
NCT01614223
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Arthrex, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

autologous plasma (2 trials)

Drugs in Phase 1 Trials (1)

Filgrastim (neupogen) (1 trial)

Drugs in Other Trials (5)

betamethasone (celestone) (1 trial)

lonapegsomatropin (Skytrofa) (1 trial)

platelet-rich plasma (1 trial)

sodium chloride (1 trial)

whole blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Musculoskeletal Diseases (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 7